Bektas Isik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bektas Isik has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Necip Arici
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Adana 01230, Türkiye
12 shared publications - Hilmi Erdem Sumbul
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Adana 01230, Türkiye
12 shared publications - Huseyin Ali Ozturk
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Adana 01230, Türkiye
12 shared publications - Ahmet Gazi Mustan
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Adana 01230, Türkiye
10 shared publications - Cahit Dincer
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Adana 01230, Türkiye
10 shared publications - Irfan Alisan
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Adana 01230, Türkiye
9 shared publications
Latest Publications
- Open Access
Treatment-Intensity Associations of Atorvastatin Therapy with Albuminuria and Liver Stiffness in Patients with Type 2 Diabetes and Hyperlipidemia: The ALI-STAR Study
Background/Objectives: Diabetic kidney disease (DKD) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in patients with type 2 diabetes mellitus (T2DM) and share common pathophysiological mechanisms. Although atorvastatin has been investigated for potential renal and hepatic effects, real-world evidence regarding its associations with both renal and hepatic surrogate markers remains limited. This study investigated the association between atorvastatin therapy and longitudinal changes in urinary albumin-to-creatinine ratio (UACR) and liver stiffness measured by vibration-controlled transient elastography (VCTE) in patients with T2DM. Methods: This retrospective observational study included 612 patients with T2DM who were categorized into three groups according to atorvastatin treatment: no statin (n = 198), atorvastatin 10–20 mg/day (n = 205), and atorvastatin 40 mg/day (n = 209). UACR and liver stiffness were assessed at baseline and after six months. Between-group comparisons and multivariable linear regression analyses were performed to evaluate the independent association of atorvastatin therapy with changes in renal and hepatic surrogate markers. Results: Baseline UACR and liver stiffness were comparable among the three groups. During six months of follow-up, UACR increased in the no-statin group (+8.64 mg/g) but decreased significantly in the atorvastatin 10–20 mg (−27.68 mg/g) and 40 mg (−44.64 mg/g) groups (overall p < 0.001). Similarly, liver stiffness remained unchanged in the no-statin group (−0.02 kPa) but decreased by 0.42 kPa and 0.93 kPa in the atorvastatin 10–20 mg and 40 mg groups, respectively (overall p < 0.001). In multivariable models adjusted for baseline outcome values and relevant clinical covariates, both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group (all p < 0.001). Conclusions: Atorvastatin treatment intensity was associated with differences in six-month UACR and liver stiffness in patients with T2DM, with numerically greater reductions observed in the 40 mg/day group. These observational findings are hypothesis-generating and require confirmation in prospective studies before causal or long-term clinical benefits can be established.
Open AccessTreatment-Intensity Associations of Atorvastatin Therapy with Albuminuria and Liver Stiffness in Patients with Type 2 Diabetes and Hyperlipidemia: The ALI-STAR Study
Background/Objectives: Diabetic kidney disease (DKD) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in patients with type 2 diabetes mellitus (T2DM) and share common pathophysiological mechanisms. Although atorvastatin has been investigated for potential renal and hepatic effects, real-world evidence regarding its associations with both renal and hepatic surrogate markers remains limited. This study investigated the association between atorvastatin therapy and longitudinal changes in urinary albumin-to-creatinine ratio (UACR) and liver stiffness measured by vibration-controlled transient elastography (VCTE) in patients with T2DM. Methods: This retrospective observational study included 612 patients with T2DM who were categorized into three groups according to atorvastatin treatment: no statin (n = 198), atorvastatin 10–20 mg/day (n = 205), and atorvastatin 40 mg/day (n = 209). UACR and liver stiffness were assessed at baseline and after six months. Between-group comparisons and multivariable linear regression analyses were performed to evaluate the independent association of atorvastatin therapy with changes in renal and hepatic surrogate markers. Results: Baseline UACR and liver stiffness were comparable among the three groups. During six months of follow-up, UACR increased in the no-statin group (+8.64 mg/g) but decreased significantly in the atorvastatin 10–20 mg (−27.68 mg/g) and 40 mg (−44.64 mg/g) groups (overall p < 0.001). Similarly, liver stiffness remained unchanged in the no-statin group (−0.02 kPa) but decreased by 0.42 kPa and 0.93 kPa in the atorvastatin 10–20 mg and 40 mg groups, respectively (overall p < 0.001). In multivariable models adjusted for baseline outcome values and relevant clinical covariates, both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group (all p < 0.001). Conclusions: Atorvastatin treatment intensity was associated with differences in six-month UACR and liver stiffness in patients with T2DM, with numerically greater reductions observed in the 40 mg/day group. These observational findings are hypothesis-generating and require confirmation in prospective studies before causal or long-term clinical benefits can be established.
- Open Access
C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide
Background and Objective: To compare longitudinal changes in serum C-peptide during dipeptidyl peptidase-4 (DPP-4) inhibitor versus sodium–glucose cotransporter 2 (SGLT2) inhibitor therapy in type 2 diabetes and to evaluate whether baseline C-peptide predicts glycemic response. Materials and Methods: This single-center retrospective new-user cohort study included 196 adults with type 2 diabetes who initiated a DPP-4 inhibitor (n = 99) or an SGLT2 inhibitor (n = 97) following a 12-month washout period. Baseline and follow-up HbA1c, plasma glucose, and fasting C-peptide measurements were assessed over a mean follow-up of 156 days. Glycemic response was defined as an HbA1c reduction of at least 1.0 percentage point. Multivariable linear and logistic regression analyses were performed, and receiver operating characteristic analysis evaluated the predictive performance of baseline C-peptide. Results: HbA1c decreased significantly in both groups, with no between-group difference in HbA1c reduction (1.03 ± 0.87 vs. 0.97 ± 0.83 percentage points; p = 0.650). C-peptide increased significantly in the DPP-4 inhibitor group but not in the SGLT2 inhibitor group (0.18 ± 0.44 vs. 0.03 ± 0.38 ng/mL; between-group p = 0.010). DPP-4 inhibitor therapy remained independently associated with higher follow-up C-peptide (adjusted β = 0.149; p = 0.013). Baseline C-peptide independently predicted glycemic response (adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001), whereas treatment class and the treatment-by-C-peptide interaction were not significant. Baseline C-peptide showed good discrimination for response (AUC = 0.805), with a Youden-derived exploratory cut-off of 2.33 ng/mL. Conclusions: DPP-4 inhibitors were associated with a greater increase in fasting C-peptide than SGLT2 inhibitors despite similar glycemic improvement; however, fasting C-peptide change alone should not be interpreted as direct evidence of improved or preserved β-cell function. Higher baseline C-peptide was associated with glycemic response in both treatment groups, although external validation is required before clinical application.
Open AccessC-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide
Background and Objective: To compare longitudinal changes in serum C-peptide during dipeptidyl peptidase-4 (DPP-4) inhibitor versus sodium–glucose cotransporter 2 (SGLT2) inhibitor therapy in type 2 diabetes and to evaluate whether baseline C-peptide predicts glycemic response. Materials and Methods: This single-center retrospective new-user cohort study included 196 adults with type 2 diabetes who initiated a DPP-4 inhibitor (n = 99) or an SGLT2 inhibitor (n = 97) following a 12-month washout period. Baseline and follow-up HbA1c, plasma glucose, and fasting C-peptide measurements were assessed over a mean follow-up of 156 days. Glycemic response was defined as an HbA1c reduction of at least 1.0 percentage point. Multivariable linear and logistic regression analyses were performed, and receiver operating characteristic analysis evaluated the predictive performance of baseline C-peptide. Results: HbA1c decreased significantly in both groups, with no between-group difference in HbA1c reduction (1.03 ± 0.87 vs. 0.97 ± 0.83 percentage points; p = 0.650). C-peptide increased significantly in the DPP-4 inhibitor group but not in the SGLT2 inhibitor group (0.18 ± 0.44 vs. 0.03 ± 0.38 ng/mL; between-group p = 0.010). DPP-4 inhibitor therapy remained independently associated with higher follow-up C-peptide (adjusted β = 0.149; p = 0.013). Baseline C-peptide independently predicted glycemic response (adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001), whereas treatment class and the treatment-by-C-peptide interaction were not significant. Baseline C-peptide showed good discrimination for response (AUC = 0.805), with a Youden-derived exploratory cut-off of 2.33 ng/mL. Conclusions: DPP-4 inhibitors were associated with a greater increase in fasting C-peptide than SGLT2 inhibitors despite similar glycemic improvement; however, fasting C-peptide change alone should not be interpreted as direct evidence of improved or preserved β-cell function. Higher baseline C-peptide was associated with glycemic response in both treatment groups, although external validation is required before clinical application.
- Open Access
- 7 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7722
Changes in Symptoms and Lung Function During Three Months of Individually Tailored Inhaled Therapy in Chronic Obstructive Pulmonary Disease: A Prospective Observational Cohort Study
Background. Randomised controlled trials have established what individual inhaled regimens can achieve in chronic obstructive pulmonary disease (COPD) under controlled conditions, but they recruit selected populations and enforce protocol-driven follow-up. How patients fare on regimens chosen individually for them in everyday care is less well characterised. Objective. To assess the change in symptoms and lung function over three months in a prospective cohort of patients with COPD whose inhaled treatment was tailored to the individual by the attending physician. Methods. Consecutive adults with stable, spirometrically confirmed COPD attending a single internal-medicine clinic were assessed at baseline and reassessed approximately three months later. Baseline regimens were short-acting beta2-agonist/short-acting muscarinic antagonist (SABA/SAMA), long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA), LABA plus inhaled corticosteroid (ICS), LABA plus LAMA, or LABA plus LAMA plus ICS. The primary outcomes were the within-participant change in COPD Assessment Test (CAT) score and in forced expiratory volume in one second (FEV1) % predicted. Secondary outcomes were the proportion achieving the CAT minimal clinically important difference (MCID, defined as a reduction of at least two points), the proportion achieving a six-minute walk distance (6MWD) improvement of at least 30 m, change in modified Medical Research Council (mMRC) dyspnoea grade, body mass index–airflow obstruction–dyspnoea–exercise capacity (BODE) and age–dyspnoea–obstruction (ADO) indices, and clinical events. Paired changes were analysed with paired t-tests or Wilcoxon signed-rank tests and are reported with 95% confidence intervals (CIs). Results. Three hundred participants were enrolled. Recorded GOLD groups were A (n = 69), B (n = 158) and E (n = 73). Paired CAT and FEV1 data were available for 276 (92.0%) and 257 (85.7%) participants, all of whom were reassessed between 84 and 98 days after baseline (median 91 days). Across the cohort, mean CAT fell by 3.93 points (95% CI −4.43 to −3.44) and mean FEV1 rose by 2.20 percentage points (95% CI 1.78 to 2.63); one hundred and ninety-five of 276 participants (70.7%) reached the CAT MCID and 98 of 244 (40.2%) achieved a 6MWD gain of at least 30 m. Improvement was observed with every long-acting regimen. Participants receiving LABA + ICS improved by 4.18 CAT points (95% CI −5.24 to −3.12; p < 0.001) and 3.06 FEV1 percentage points (95% CI 2.16 to 3.95; p < 0.001), with 82.1% reaching the CAT MCID—a magnitude similar to that observed on LABA+LAMA. Participants on SABA/SAMA alone showed no improvement in either outcome. Sixty-three exacerbations, eleven hospitalisations and four cases of pneumonia occurred. Conclusions. During a reassessment interval of 84 to 98 days, patients with COPD receiving individually tailored long-acting inhaled therapy showed improvement in symptoms and lung function that exceeded the established MCID for the CAT, including patients treated with LABA+ICS. The study had no concurrent control group, no randomisation and no adjustment for baseline differences between regimens; the observed changes therefore describe the course of treated patients and cannot be attributed to any specific regimen.
- 7 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7722
Open AccessChanges in Symptoms and Lung Function During Three Months of Individually Tailored Inhaled Therapy in Chronic Obstructive Pulmonary Disease: A Prospective Observational Cohort Study
Background. Randomised controlled trials have established what individual inhaled regimens can achieve in chronic obstructive pulmonary disease (COPD) under controlled conditions, but they recruit selected populations and enforce protocol-driven follow-up. How patients fare on regimens chosen individually for them in everyday care is less well characterised. Objective. To assess the change in symptoms and lung function over three months in a prospective cohort of patients with COPD whose inhaled treatment was tailored to the individual by the attending physician. Methods. Consecutive adults with stable, spirometrically confirmed COPD attending a single internal-medicine clinic were assessed at baseline and reassessed approximately three months later. Baseline regimens were short-acting beta2-agonist/short-acting muscarinic antagonist (SABA/SAMA), long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA), LABA plus inhaled corticosteroid (ICS), LABA plus LAMA, or LABA plus LAMA plus ICS. The primary outcomes were the within-participant change in COPD Assessment Test (CAT) score and in forced expiratory volume in one second (FEV1) % predicted. Secondary outcomes were the proportion achieving the CAT minimal clinically important difference (MCID, defined as a reduction of at least two points), the proportion achieving a six-minute walk distance (6MWD) improvement of at least 30 m, change in modified Medical Research Council (mMRC) dyspnoea grade, body mass index–airflow obstruction–dyspnoea–exercise capacity (BODE) and age–dyspnoea–obstruction (ADO) indices, and clinical events. Paired changes were analysed with paired t-tests or Wilcoxon signed-rank tests and are reported with 95% confidence intervals (CIs). Results. Three hundred participants were enrolled. Recorded GOLD groups were A (n = 69), B (n = 158) and E (n = 73). Paired CAT and FEV1 data were available for 276 (92.0%) and 257 (85.7%) participants, all of whom were reassessed between 84 and 98 days after baseline (median 91 days). Across the cohort, mean CAT fell by 3.93 points (95% CI −4.43 to −3.44) and mean FEV1 rose by 2.20 percentage points (95% CI 1.78 to 2.63); one hundred and ninety-five of 276 participants (70.7%) reached the CAT MCID and 98 of 244 (40.2%) achieved a 6MWD gain of at least 30 m. Improvement was observed with every long-acting regimen. Participants receiving LABA + ICS improved by 4.18 CAT points (95% CI −5.24 to −3.12; p < 0.001) and 3.06 FEV1 percentage points (95% CI 2.16 to 3.95; p < 0.001), with 82.1% reaching the CAT MCID—a magnitude similar to that observed on LABA+LAMA. Participants on SABA/SAMA alone showed no improvement in either outcome. Sixty-three exacerbations, eleven hospitalisations and four cases of pneumonia occurred. Conclusions. During a reassessment interval of 84 to 98 days, patients with COPD receiving individually tailored long-acting inhaled therapy showed improvement in symptoms and lung function that exceeded the established MCID for the CAT, including patients treated with LABA+ICS. The study had no concurrent control group, no randomisation and no adjustment for baseline differences between regimens; the observed changes therefore describe the course of treated patients and cannot be attributed to any specific regimen.
- Open Access
- 30 September 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (3) , 982-991
TSH Levels Are Predictive of Malignancy in Preoperative Thyroid Nodules: Our Single-Center Experience
Objective: To evaluate the association between preoperative thyroid-stimulating hormone (TSH) levels and postoperative histopathological malignancy in patients undergoing thyroidectomy for thyroid nodules, and to compare the discriminative performance of TSH with that of TI-RADS.Material and Methods: A total of 366 patients operated for thyroid nodules between January 1, 2023 and January 1, 2025 at a tertiary center were retrospectively reviewed. Preoperative TSH, fT3, fT4 and routine biochemical parameters, TI-RADS score, fine-needle aspiration biopsy (FNAB) cytology and type of surgery were recorded. Patients were dichotomized as benign or malignant according to final pathology. ROC analysis was performed for TSH and TI-RADS, with the optimal cut-off determined by the Youden index. Variables associated with malignancy were assessed by univariate and multivariate logistic regression.Results: Final pathology was benign in 223 patients (60.9%) and malignant in 143 (39.1%). Groups were comparable for age and sex (p=0.737 and p=0.477, respectively). TSH was significantly higher in the malignant group (median 1.250 vs 1.115 µIU/mL; p=0.029), as was fT3 (p=0.010). The AUC was low for TSH (0.572; 95% CI: 0.508–0.636) but substantially higher for TI-RADS (0.802; 95% CI: 0.752–0.853). The Youden-derived TSH cut-off was 0.687 µIU/mL (sensitivity 85.8%, specificity 32.8%). In multivariate analysis, TSH ≥0.687 µIU/mL (OR=6.10; 95% CI: 2.28–16.33), TI-RADS score (OR=3.58; 2.25–5.69) and non-benign FNAB cytology (OR=16.04; 6.63–38.79) were independently associated with malignancy (all p
- 30 September 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (3) , 982-991
Open AccessTSH Levels Are Predictive of Malignancy in Preoperative Thyroid Nodules: Our Single-Center Experience
Objective: To evaluate the association between preoperative thyroid-stimulating hormone (TSH) levels and postoperative histopathological malignancy in patients undergoing thyroidectomy for thyroid nodules, and to compare the discriminative performance of TSH with that of TI-RADS.Material and Methods: A total of 366 patients operated for thyroid nodules between January 1, 2023 and January 1, 2025 at a tertiary center were retrospectively reviewed. Preoperative TSH, fT3, fT4 and routine biochemical parameters, TI-RADS score, fine-needle aspiration biopsy (FNAB) cytology and type of surgery were recorded. Patients were dichotomized as benign or malignant according to final pathology. ROC analysis was performed for TSH and TI-RADS, with the optimal cut-off determined by the Youden index. Variables associated with malignancy were assessed by univariate and multivariate logistic regression.Results: Final pathology was benign in 223 patients (60.9%) and malignant in 143 (39.1%). Groups were comparable for age and sex (p=0.737 and p=0.477, respectively). TSH was significantly higher in the malignant group (median 1.250 vs 1.115 µIU/mL; p=0.029), as was fT3 (p=0.010). The AUC was low for TSH (0.572; 95% CI: 0.508–0.636) but substantially higher for TI-RADS (0.802; 95% CI: 0.752–0.853). The Youden-derived TSH cut-off was 0.687 µIU/mL (sensitivity 85.8%, specificity 32.8%). In multivariate analysis, TSH ≥0.687 µIU/mL (OR=6.10; 95% CI: 2.28–16.33), TI-RADS score (OR=3.58; 2.25–5.69) and non-benign FNAB cytology (OR=16.04; 6.63–38.79) were independently associated with malignancy (all p
- Open Access
- 8 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6950
Low Serum C-Peptide and Albuminuria Severity in Type 2 Diabetes Mellitus: A Cross-Sectional Study
Background/Objectives: Lower serum C-peptide, reflecting reduced beta-cell reserve, has been linked to diabetic complications, but whether these associations are independent of diabetes duration and glycaemic control is unclear. The objective of this study was to determine which microvascular and macrovascular complications of type 2 diabetes mellitus (T2DM) remain associated with fasting C-peptide after adjustment for these factors. Methods: In this single-centre, cross-sectional study with consecutive prospective enrolment, non-pregnant adults with an established diagnosis of T2DM attending routine outpatient follow-up were eligible; those with pancreatic malignancy or exocrine pancreatic insufficiency, monogenic or autoimmune diabetes, or acute hyperglycaemic crises were excluded. A total of 590 patients were stratified by fasting C-peptide into insufficient (n = 35), borderline (1.0–1.8 ng/mL; n = 212) and normal/high (≥1.8 ng/mL; n = 343) groups. Logistic regression adjusted for age, sex, diabetes duration, HbA1c and body mass index assessed each complication. Receiver operating characteristic analysis using DeLong’s test assessed incremental discrimination. Results: In the unadjusted analyses, every complication was more frequent at lower C-peptide. After adjustment, C-peptide was not associated with the presence of albuminuria (insufficient versus normal/high, odds ratio 1.60, 95% CI 0.16–15.86) but was strongly associated with its severity: for severely increased or nephrotic-range albuminuria, the adjusted odds ratios were 13.47 (5.33–34.07) and 6.90 (3.83–12.44) in the insufficient and borderline groups (both p < 0.001). Adding C-peptide to a model of diabetes duration, HbA1c and fasting glucose was associated with a statistically significant, but modest, improvement in discrimination for severe albuminuria (area under the curve of 0.748 to 0.783; ΔAUC = 0.035, p = 0.027). Associations with macrovascular complications were present in the unadjusted analyses but were substantially attenuated after adjustment and no longer statistically significant, except for peripheral arterial disease and foot ulcer, which remained associated with insufficient C-peptide in models based on small numbers of events and should be regarded as exploratory. Conclusions: Low C-peptide was independently associated with the severity of albuminuria rather than its presence and was associated with a modest incremental improvement in discrimination. These exploratory findings suggest that C-peptide, an inexpensive and widely available measurement, may provide information associated with advanced diabetic kidney disease; prospective, externally validated studies are needed before clinical application.
- 8 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6950
Open AccessLow Serum C-Peptide and Albuminuria Severity in Type 2 Diabetes Mellitus: A Cross-Sectional Study
Background/Objectives: Lower serum C-peptide, reflecting reduced beta-cell reserve, has been linked to diabetic complications, but whether these associations are independent of diabetes duration and glycaemic control is unclear. The objective of this study was to determine which microvascular and macrovascular complications of type 2 diabetes mellitus (T2DM) remain associated with fasting C-peptide after adjustment for these factors. Methods: In this single-centre, cross-sectional study with consecutive prospective enrolment, non-pregnant adults with an established diagnosis of T2DM attending routine outpatient follow-up were eligible; those with pancreatic malignancy or exocrine pancreatic insufficiency, monogenic or autoimmune diabetes, or acute hyperglycaemic crises were excluded. A total of 590 patients were stratified by fasting C-peptide into insufficient (n = 35), borderline (1.0–1.8 ng/mL; n = 212) and normal/high (≥1.8 ng/mL; n = 343) groups. Logistic regression adjusted for age, sex, diabetes duration, HbA1c and body mass index assessed each complication. Receiver operating characteristic analysis using DeLong’s test assessed incremental discrimination. Results: In the unadjusted analyses, every complication was more frequent at lower C-peptide. After adjustment, C-peptide was not associated with the presence of albuminuria (insufficient versus normal/high, odds ratio 1.60, 95% CI 0.16–15.86) but was strongly associated with its severity: for severely increased or nephrotic-range albuminuria, the adjusted odds ratios were 13.47 (5.33–34.07) and 6.90 (3.83–12.44) in the insufficient and borderline groups (both p < 0.001). Adding C-peptide to a model of diabetes duration, HbA1c and fasting glucose was associated with a statistically significant, but modest, improvement in discrimination for severe albuminuria (area under the curve of 0.748 to 0.783; ΔAUC = 0.035, p = 0.027). Associations with macrovascular complications were present in the unadjusted analyses but were substantially attenuated after adjustment and no longer statistically significant, except for peripheral arterial disease and foot ulcer, which remained associated with insufficient C-peptide in models based on small numbers of events and should be regarded as exploratory. Conclusions: Low C-peptide was independently associated with the severity of albuminuria rather than its presence and was associated with a modest incremental improvement in discrimination. These exploratory findings suggest that C-peptide, an inexpensive and widely available measurement, may provide information associated with advanced diabetic kidney disease; prospective, externally validated studies are needed before clinical application.
- Open Access
- 6 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 6106
Diabetic Retinopathy Grading and Concurrent Cardiorenal Biomarker Abnormalities in Type 2 Diabetes: Albuminuria and Elevated NT-proBNP—A Retrospective Cross-Sectional Study
Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a recognised marker of systemic vascular injury. Whether DR—graded independently by two experienced ophthalmologists as part of routine institutional care—is independently associated with concurrent nephropathy (urine albumin-to-creatinine ratio [UACR] ≥ 30 mg/g) and subclinical cardiac stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥ 125 pg/mL) remains insufficiently examined. Methods: Retrospective cross-sectional study of 401 T2DM adults who underwent dilated fundus examination independently graded by two board-certified ophthalmologists (each ≥ 10 years’ experience in diabetic eye disease) using ETDRS-based classification. Inter-physician agreement was quantified by Cohen’s weighted kappa. The primary composite outcome was concurrent nephropathy and subclinical cardiac stress. Multivariable logistic regression adjusted for age, sex, HbA1c, diabetes duration, eGFR, hypertension, and pharmacological treatments. Results: The composite outcome was present in 120 (64.2%) DR-positive vs. 14 (6.5%) DR-negative patients (crude OR: 25.59 (13.78–47.51); p < 0.001; fully adjusted OR: 21.49 (11.02–41.81); p < 0.001). Inter-physician agreement was high (Cohen’s weighted κ = 0.88; 95% CI: 0.83–0.93). Nephropathy alone was found in 164 (87.7%) vs. 76 (35.5%) patients (OR: 12.95 (7.71–21.75); p < 0.001), and elevated NT-proBNP in 137 (73.3%) vs. 39 (18.2%) patients (OR: 12.29 (7.65–19.76); p < 0.001). A significant trend across DR severity grades was observed (p for trend < 0.001), although the gradient was not strictly monotonic. ROC AUC = 0.837 (95% CI: 0.784–0.860). Conclusions: Ophthalmologist-graded DR was independently associated with the concurrent presence of albuminuria and elevated NT-proBNP in T2DM. Because the design is cross-sectional, these findings describe association rather than prediction or causation. They generate the hypothesis that retinal grading may help flag patients in whom cardiorenal biomarker assessment is worth considering, but prospective validation is required before any screening application.
- 6 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 6106
Open AccessDiabetic Retinopathy Grading and Concurrent Cardiorenal Biomarker Abnormalities in Type 2 Diabetes: Albuminuria and Elevated NT-proBNP—A Retrospective Cross-Sectional Study
Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a recognised marker of systemic vascular injury. Whether DR—graded independently by two experienced ophthalmologists as part of routine institutional care—is independently associated with concurrent nephropathy (urine albumin-to-creatinine ratio [UACR] ≥ 30 mg/g) and subclinical cardiac stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥ 125 pg/mL) remains insufficiently examined. Methods: Retrospective cross-sectional study of 401 T2DM adults who underwent dilated fundus examination independently graded by two board-certified ophthalmologists (each ≥ 10 years’ experience in diabetic eye disease) using ETDRS-based classification. Inter-physician agreement was quantified by Cohen’s weighted kappa. The primary composite outcome was concurrent nephropathy and subclinical cardiac stress. Multivariable logistic regression adjusted for age, sex, HbA1c, diabetes duration, eGFR, hypertension, and pharmacological treatments. Results: The composite outcome was present in 120 (64.2%) DR-positive vs. 14 (6.5%) DR-negative patients (crude OR: 25.59 (13.78–47.51); p < 0.001; fully adjusted OR: 21.49 (11.02–41.81); p < 0.001). Inter-physician agreement was high (Cohen’s weighted κ = 0.88; 95% CI: 0.83–0.93). Nephropathy alone was found in 164 (87.7%) vs. 76 (35.5%) patients (OR: 12.95 (7.71–21.75); p < 0.001), and elevated NT-proBNP in 137 (73.3%) vs. 39 (18.2%) patients (OR: 12.29 (7.65–19.76); p < 0.001). A significant trend across DR severity grades was observed (p for trend < 0.001), although the gradient was not strictly monotonic. ROC AUC = 0.837 (95% CI: 0.784–0.860). Conclusions: Ophthalmologist-graded DR was independently associated with the concurrent presence of albuminuria and elevated NT-proBNP in T2DM. Because the design is cross-sectional, these findings describe association rather than prediction or causation. They generate the hypothesis that retinal grading may help flag patients in whom cardiorenal biomarker assessment is worth considering, but prospective validation is required before any screening application.
- Open Access
- 26 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4105
Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study
Background: Several studies have demonstrated that adding semaglutide to the treatment of patients with type 2 diabetes mellitus (T2DM) reduces insulin requirements and glycated hemoglobin (HbA1c) levels. This study aimed to investigate real-world evidence for the effects of semaglutide dose escalation on HbA1c, body weight, dyslipidemia, and insulin dose reduction in patients with T2DM in the Cukurova region of Türkiye. Methods: This retrospective cohort study enrolled 500 patients (255 male, 245 female; mean age 56.1 ± 10.8 years) who initiated semaglutide therapy for T2DM between 2024 and 2025. Patients were grouped according to their maximum semaglutide dose: 0.25 mg (Group I), 0.50 mg (Group II), and 1.00 mg (Group III). The primary endpoint was the change in HbA1c from baseline to end of study (30 weeks) across semaglutide dose escalation groups. Secondary endpoints included changes in body weight, frequency of insulin dose reduction, and effects on lipid parameters. Results: A total of 117 patients (23.4%) discontinued semaglutide therapy, while 383 patients (76.6%) completed the study. The primary endpoint revealed a mean HbA1c reduction of −1.03 ± 0.35% from baseline to end of study (95% CI 0.99–1.07; t = 58.644; p < 0.001). Reductions in HbA1c increased progressively from Group I to Group III (HbA1c: −0.72 ± 0.28, −1.02 ± 0.26, −1.27 ± 0.34%). Insulin dose reduction frequency increased significantly from Group I to Group III (40%, 41%, and 51%, respectively; p = 0.010), with a statistically significant difference only between Group I and Group III. At the end of follow-up, rates of hypoglycemic episodes and gastrointestinal (GI) adverse events were similar across groups. Conclusions: In a real-world population from the Cukurova region of Türkiye, semaglutide dose escalation in T2DM patients achieved clinically meaningful glycemic control, body weight reduction, LDL-cholesterol lowering, and a significant increase in insulin dose reduction frequency, without a significant increase in GI adverse events.
- 26 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4105
Open AccessEvaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study
Background: Several studies have demonstrated that adding semaglutide to the treatment of patients with type 2 diabetes mellitus (T2DM) reduces insulin requirements and glycated hemoglobin (HbA1c) levels. This study aimed to investigate real-world evidence for the effects of semaglutide dose escalation on HbA1c, body weight, dyslipidemia, and insulin dose reduction in patients with T2DM in the Cukurova region of Türkiye. Methods: This retrospective cohort study enrolled 500 patients (255 male, 245 female; mean age 56.1 ± 10.8 years) who initiated semaglutide therapy for T2DM between 2024 and 2025. Patients were grouped according to their maximum semaglutide dose: 0.25 mg (Group I), 0.50 mg (Group II), and 1.00 mg (Group III). The primary endpoint was the change in HbA1c from baseline to end of study (30 weeks) across semaglutide dose escalation groups. Secondary endpoints included changes in body weight, frequency of insulin dose reduction, and effects on lipid parameters. Results: A total of 117 patients (23.4%) discontinued semaglutide therapy, while 383 patients (76.6%) completed the study. The primary endpoint revealed a mean HbA1c reduction of −1.03 ± 0.35% from baseline to end of study (95% CI 0.99–1.07; t = 58.644; p < 0.001). Reductions in HbA1c increased progressively from Group I to Group III (HbA1c: −0.72 ± 0.28, −1.02 ± 0.26, −1.27 ± 0.34%). Insulin dose reduction frequency increased significantly from Group I to Group III (40%, 41%, and 51%, respectively; p = 0.010), with a statistically significant difference only between Group I and Group III. At the end of follow-up, rates of hypoglycemic episodes and gastrointestinal (GI) adverse events were similar across groups. Conclusions: In a real-world population from the Cukurova region of Türkiye, semaglutide dose escalation in T2DM patients achieved clinically meaningful glycemic control, body weight reduction, LDL-cholesterol lowering, and a significant increase in insulin dose reduction frequency, without a significant increase in GI adverse events.
- Open Access
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3535
Hidden Burden of Hypertension in Türkiye: A Multi-Center DAHUDER World Hypertension Day Study Reveals Gaps in Awareness, Adherence, and Control
Background: Hypertension remains the single most important modifiable risk factor for cardiovascular disease, stroke, and premature mortality worldwide. Despite major pharmacological advances, awareness, treatment, and control rates remain globally inadequate, particularly in low- and middle-income settings. Türkiye occupies a unique epidemiological position at the intersection of European and Asian cardiovascular risk patterns, with national surveys documenting a stable hypertension prevalence of approximately 30% but persistent deficits in disease control. Methods: This cross-sectional study was conducted on World Hypertension Day (17 May 2025) across nine provinces in Türkiye representing five geographic regions (Marmara, Aegean, Mediterranean, Black Sea, and Southeastern Anatolia). A total of 1967 adult volunteers were enrolled. Blood pressure was measured following standardized protocols and classified per ESH 2023 guidelines. A structured questionnaire captured sociodemographic data, lifestyle factors, medication adherence, and hypertension-related awareness. Results: The median participant age was 51 years; 55.4% were female. Screening-detected hypertension (BP ≥ 140/90 mmHg) was identified in 26.6% and above-optimal blood pressure in 41.6%. A prior hypertension diagnosis was reported by 35.1%. Among the 1277 participants without a known diagnosis, 51.1% had above-optimal or hypertension-range blood pressure readings, including 11.6% with screening-detected hypertension-range blood pressure. Independent predictors in multivariate analysis included age (OR = 1.048), male sex (OR = 1.528), BMI (OR = 1.096), and alcohol consumption (OR = 1.536); regular exercise was protective (OR = 0.796). Among known hypertensive patients, only 50% monitored blood pressure regularly, 30% skipped doses, and awareness of renal (40.4%) and visual (30.6%) complications was notably low. Conclusions: This large multi-center screening study reveals a substantial proportion of previously undetected hypertension-range blood pressure readings and persistent management gaps in a volunteer-based Turkish community sample. The observed screening rate below national prevalence averages likely reflects a healthy volunteer effect inherent to this study design. World Hypertension Day offers an effective framework for simultaneous multi-center screening. Targeted interventions should address non-cardiovascular complication awareness, sodium intake, and medication adherence.
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3535
Open AccessHidden Burden of Hypertension in Türkiye: A Multi-Center DAHUDER World Hypertension Day Study Reveals Gaps in Awareness, Adherence, and Control
Background: Hypertension remains the single most important modifiable risk factor for cardiovascular disease, stroke, and premature mortality worldwide. Despite major pharmacological advances, awareness, treatment, and control rates remain globally inadequate, particularly in low- and middle-income settings. Türkiye occupies a unique epidemiological position at the intersection of European and Asian cardiovascular risk patterns, with national surveys documenting a stable hypertension prevalence of approximately 30% but persistent deficits in disease control. Methods: This cross-sectional study was conducted on World Hypertension Day (17 May 2025) across nine provinces in Türkiye representing five geographic regions (Marmara, Aegean, Mediterranean, Black Sea, and Southeastern Anatolia). A total of 1967 adult volunteers were enrolled. Blood pressure was measured following standardized protocols and classified per ESH 2023 guidelines. A structured questionnaire captured sociodemographic data, lifestyle factors, medication adherence, and hypertension-related awareness. Results: The median participant age was 51 years; 55.4% were female. Screening-detected hypertension (BP ≥ 140/90 mmHg) was identified in 26.6% and above-optimal blood pressure in 41.6%. A prior hypertension diagnosis was reported by 35.1%. Among the 1277 participants without a known diagnosis, 51.1% had above-optimal or hypertension-range blood pressure readings, including 11.6% with screening-detected hypertension-range blood pressure. Independent predictors in multivariate analysis included age (OR = 1.048), male sex (OR = 1.528), BMI (OR = 1.096), and alcohol consumption (OR = 1.536); regular exercise was protective (OR = 0.796). Among known hypertensive patients, only 50% monitored blood pressure regularly, 30% skipped doses, and awareness of renal (40.4%) and visual (30.6%) complications was notably low. Conclusions: This large multi-center screening study reveals a substantial proportion of previously undetected hypertension-range blood pressure readings and persistent management gaps in a volunteer-based Turkish community sample. The observed screening rate below national prevalence averages likely reflects a healthy volunteer effect inherent to this study design. World Hypertension Day offers an effective framework for simultaneous multi-center screening. Targeted interventions should address non-cardiovascular complication awareness, sodium intake, and medication adherence.
- Open Access
- 2 September 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-9
Elabela increases in patients with primary hyperparathyroidism, especially in the presence of surgery indication
Patients with primary hyperparathyroidism (PHPT) are known to have structural and functional changes in the vascular system. Bioactive peptides associated with the apelinergic system play a role in ischemic heart disease and atherosclerosis. In this study, we aimed to investigate the changes in serum elabela, a novel apelinergic system peptide, and its relationship with aortic intima media (AIM) measurements in patients with newly diagnosed primary hyperparathyroidism. The study was prospectively conducted with 45 patients with newly diagnosed Primary Hyperparathyroidism who were admitted to the Internal Medicine outpatient clinics of Adana City Training and Research Hospital. Forty people with similar demographic characteristics were included as a healthy control group. Hemogram, biochemistry, parathormone, vitamin D, urinary calcium, dual x-ray absorptiometry (DEXA), Elabela and aortic intima media levels were measured. The study groups were divided into three groups: healthy control group (Group 1: 40 patients), PHPT group without surgical indication (Group 2: 20 patients) and PHPT group with surgical indication (Group 3: 25 patients). Elabela level was found to increase from group 1 to group 3. It was 2.1 (1.3–2.4) ng/mL in group 1, 10.45 (3.7-14.15) ng/mL in group 2 and 12.6 (12.0–14.0) ng/mL in group 3 (p < 0.001). AIM level was found to be statistically significantly higher in group 3 compared to groups 1 and 2. It was 1.2 (1.0-1.4) mm in group 1, 1.3 (1.2–1.6) mm in group 2 and 2.15 (1.95–2.32) mm in group 3 (p < 0.001). Linear regression analysis performed with the parameters significantly correlated with Elabela in group 3 showed that DEXA and AIM levels were independently associated with Elabela. In the multivariate logistic regression analysis performed for the independent determination of patients with surgical indication in the patient group, it was found that Elabela level independently determined the group with surgical indication. According to this analysis, each 1 unit increase in Elabela level increased the probability of surgery by 30.9% in the patient group. In patients with primary hyperparathyroidism, serum Elabela level may be increased due to activation of the Apelinergic system in response to adverse vascular and cardiac effects that may be caused by increased parathormone. Elabela level can be used to determine the indication for surgery in PHPT patients.
- 2 September 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-9
Open AccessElabela increases in patients with primary hyperparathyroidism, especially in the presence of surgery indication
Patients with primary hyperparathyroidism (PHPT) are known to have structural and functional changes in the vascular system. Bioactive peptides associated with the apelinergic system play a role in ischemic heart disease and atherosclerosis. In this study, we aimed to investigate the changes in serum elabela, a novel apelinergic system peptide, and its relationship with aortic intima media (AIM) measurements in patients with newly diagnosed primary hyperparathyroidism. The study was prospectively conducted with 45 patients with newly diagnosed Primary Hyperparathyroidism who were admitted to the Internal Medicine outpatient clinics of Adana City Training and Research Hospital. Forty people with similar demographic characteristics were included as a healthy control group. Hemogram, biochemistry, parathormone, vitamin D, urinary calcium, dual x-ray absorptiometry (DEXA), Elabela and aortic intima media levels were measured. The study groups were divided into three groups: healthy control group (Group 1: 40 patients), PHPT group without surgical indication (Group 2: 20 patients) and PHPT group with surgical indication (Group 3: 25 patients). Elabela level was found to increase from group 1 to group 3. It was 2.1 (1.3–2.4) ng/mL in group 1, 10.45 (3.7-14.15) ng/mL in group 2 and 12.6 (12.0–14.0) ng/mL in group 3 (p < 0.001). AIM level was found to be statistically significantly higher in group 3 compared to groups 1 and 2. It was 1.2 (1.0-1.4) mm in group 1, 1.3 (1.2–1.6) mm in group 2 and 2.15 (1.95–2.32) mm in group 3 (p < 0.001). Linear regression analysis performed with the parameters significantly correlated with Elabela in group 3 showed that DEXA and AIM levels were independently associated with Elabela. In the multivariate logistic regression analysis performed for the independent determination of patients with surgical indication in the patient group, it was found that Elabela level independently determined the group with surgical indication. According to this analysis, each 1 unit increase in Elabela level increased the probability of surgery by 30.9% in the patient group. In patients with primary hyperparathyroidism, serum Elabela level may be increased due to activation of the Apelinergic system in response to adverse vascular and cardiac effects that may be caused by increased parathormone. Elabela level can be used to determine the indication for surgery in PHPT patients.